Since both BRCC3 mutated patients had a t(8;21)(q22;q22.1) and no BRCC3 mutations were found in other types of AML we included BRCC3 in a targeted sequencing study with a total of 351 patients with core-binding-factor AML including 191 patients with t(8;21)(q22;q22.1) and 160 patients with inv(16)(p13.1q22) [30]. The gene discussed is BRCC3; the disease is acute myeloid leukemia.